Meantime, the UK Parliament has been told that the Medicines Control Agency has investigated specific complaints about the quality of medicines produced by generic companies and found them to be largely unsubstantiated, the Pharmaceutical Journal reports.
In a written Parliamentary reply, MCA chief executive Keith Jones was quoted as also noting that "while deficiencies do occasionally occur in both generic and innovator products, there is no evidence from the results of testing carried out by the Medicines Testing Scheme over the past two years to suggest that generic medicines are of inferior quality compared with the equivalent innovator products."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze